share_log

SenesTech | 8-K: Current report

SenesTech | 8-K: Current report

SenesTech | 8-K：重大事件
美股SEC公告 ·  06/20 16:03

Moomoo AI 已提取核心信息

On June 20, 2024, SenesTech, Inc., a biotechnology company based in Phoenix, Arizona, announced the entry into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. Under this agreement, SenesTech may offer and sell shares of its common stock at its discretion in 'at the market' offerings, potentially raising aggregate gross proceeds of up to $1,575,944. The sales will be conducted pursuant to a shelf registration statement and related prospectus supplement filed with the SEC. The agreement allows Wainwright to sell shares through various methods, including directly on the Nasdaq, where SenesTech's common stock is listed under the symbol SNES. SenesTech is not obligated to sell any specific number of shares, and Wainwright will act based on SenesTech's instructions, subject to a 3.0% placement fee on the gross sales price. The offering will terminate upon reaching the maximum sales amount or by mutual termination of the agreement. The company has also provided customary indemnification rights to Wainwright and will reimburse certain expenses related to the agreement.
On June 20, 2024, SenesTech, Inc., a biotechnology company based in Phoenix, Arizona, announced the entry into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. Under this agreement, SenesTech may offer and sell shares of its common stock at its discretion in 'at the market' offerings, potentially raising aggregate gross proceeds of up to $1,575,944. The sales will be conducted pursuant to a shelf registration statement and related prospectus supplement filed with the SEC. The agreement allows Wainwright to sell shares through various methods, including directly on the Nasdaq, where SenesTech's common stock is listed under the symbol SNES. SenesTech is not obligated to sell any specific number of shares, and Wainwright will act based on SenesTech's instructions, subject to a 3.0% placement fee on the gross sales price. The offering will terminate upon reaching the maximum sales amount or by mutual termination of the agreement. The company has also provided customary indemnification rights to Wainwright and will reimburse certain expenses related to the agreement.
2024年6月20日，总部位于亚利桑那州菲尼克斯的生物技术公司SenesTech, Inc.宣布与H.C. Wainwright & Co., LLC签署了一份按市场价格发行协议。根据协议，SenesTech可以在自己的决定下进行“按市场价格”发行，可能筹集总毛收益高达157万5944美元的普通股股份。此次销售将根据提交给美国证监会的一份条款及附加说明书的货架注册声明进行。根据协议，Wainwright可以通过各种方式进行销售，包括在纳斯达克直接销售，而SenesTech的普通股票在纳斯达克上标的为SNES。SenesTech没有义务出售任何特定数量的股票，而Wainwright将根据SenesTech的指示行事，但是受总销售价格的3.0%的销售费的限制。该发行将在达到最大销售金额或协议的互相终止时终止。该公司还向Wainwright提供了惯常的赔偿权，并将偿还与该协议相关的某些费用。
2024年6月20日，总部位于亚利桑那州菲尼克斯的生物技术公司SenesTech, Inc.宣布与H.C. Wainwright & Co., LLC签署了一份按市场价格发行协议。根据协议，SenesTech可以在自己的决定下进行“按市场价格”发行，可能筹集总毛收益高达157万5944美元的普通股股份。此次销售将根据提交给美国证监会的一份条款及附加说明书的货架注册声明进行。根据协议，Wainwright可以通过各种方式进行销售，包括在纳斯达克直接销售，而SenesTech的普通股票在纳斯达克上标的为SNES。SenesTech没有义务出售任何特定数量的股票，而Wainwright将根据SenesTech的指示行事，但是受总销售价格的3.0%的销售费的限制。该发行将在达到最大销售金额或协议的互相终止时终止。该公司还向Wainwright提供了惯常的赔偿权，并将偿还与该协议相关的某些费用。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间